Institut Toulousain des Maladies Infectieuses et Inflammatoires
  • News
    • Publications
    • Seminars
    • Thesis defense
    • Highlights
  • The Institute
    • Education
    • Organization chart
    • Join us
    • Financing partners
    • Directory
  • Research Teams
    • J.C. Guéry
    • M. Simon
    • N. Gaudenzio
    • R. Liblau / A. Saoudi
    • J. Ausseil / R. Poupot
    • N. Blanchard
    • D. Dunia / C. Malnou
    • J. Izopet / B. Lagane
    • N. Jabrane-Ferrat
    • J. van Meerwijk / O. Joffre
    • N. Fazilleau / S. Guerder
    • R. Lesourne / L. Dupré
    • M. Diaz Munoz
    • L. Reber
    • C. Le Coz
    • A. Dejean
  • Technical Platforms
    • Cell Imaging
    • Cytometry & Cell Sorting
    • Human immune-monitoring
    • Genomic and transcriptomic
  • Contact
  • Français
Select Page
HIV-1 cell-to-cell spread overcomes the virus entry block of non-macrophage-tropic strains in macrophages

HIV-1 cell-to-cell spread overcomes the virus entry block of non-macrophage-tropic strains in macrophages

17 Jun 2022 | Publications

HIV-1 cell-to-cell spread overcomes the virus entry block of non-macrophage-tropic strains in macrophages. Mingyu Han, Vincent Cantaloube-Ferrieu, Maorong Xie, Marie Armani-Tourret,Marie Woottum, Jean-Christophe Pagès, Philippe Colin, Bernard Lagane*, Serge Benichou*...
The anti-FcepsilonRI antibody MAR-1 depletes basophils and cross-reacts with myeloid cells through its Fc portion

The anti-FcepsilonRI antibody MAR-1 depletes basophils and cross-reacts with myeloid cells through its Fc portion

2 May 2022 | Publications

The anti-FcepsilonRI antibody MAR-1 depletes basophils and cross-reacts with myeloid cells through its Fc portion. Worrall WPM*, Kamphuis JBJ*, Stackowicz J, Mougel A, Maure E, Pecalvel C, et al Allergy. 2022; 00:1–4. MAR-1 is the only monoclonal antibody used to...
Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice

Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice

15 Jun 2021 | Publications

Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice Conde E Bertrand R, Balbino Bonnefoy Stackowicz Caillot Colaone Hamdi Houmadi Loste Kamphuis JBJ Huetz Guilleminault Gaudenzio Mougel Hardy Snouwaert JN Koller BH Serra Bruhns...
TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women

TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women

22 Jun 2020 | Publications

TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women Pascal Azar (*), José Enrique Mejía (*), Claire Cenac (*), Arnoo Shaiykova, Ali Youness, Sophie Laffont, Asma Essat, Jacques Izopet, Caroline Passaes, Michaela Müller-Trutwin, Pierre...
A Virus Hosted in Malaria-Infected Blood Protects against T Cell-Mediated Inflammatory Diseases by Impairing DC Function in a Type I IFN-Dependent Manner

A Virus Hosted in Malaria-Infected Blood Protects against T Cell-Mediated Inflammatory Diseases by Impairing DC Function in a Type I IFN-Dependent Manner

21 Apr 2020 | Publications

Viral infections: beneficial against certain inflammatory diseases? Exposure to infectious agents can affect our immune functions.  In some cases, even asymptomatic infections can improve the course of concomitant inflammatory diseases. In collaboration with A....
Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study

Long-term immunity against yellow fever in children vaccinated during infancy: a longitudinal cohort study

9 Oct 2019 | Publications

Domingo C, Fraissinet J, Ansah PO, Kelly C, Bhat N, Sow SO, Mejía JE. Yellow fever is a life-threatening viral disease endemic to tropical regions of Africa and the Americas. The vaccine against yellow fever is regarded as highly efficacious, and the World Health...
« Older Entries
Next Entries »
Crédits et mentions légales - © Agences CosiWeb & ComScience
 
Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site. Si vous continuez à utiliser ce dernier, nous considérerons que vous acceptez l'utilisation des cookies.OkEn savoir plus